Skip to main content

Table 4 Samalizumab bound to CD200+ CLL cells by cohort

From: Phase I study of samalizumab in chronic lymphocytic leukemia and multiple myeloma: blockade of the immune checkpoint CD200

Samalizumab Cohort CLL cells bound by samalizumab (%) Density of bound samalizumab (MFI)
Pre-dose Day 1 Pre-dose Day 1
50 mg/m2 (n = 4) 0.3–0.7 1.1–3.3 1.9–3.1 3.3–4.1
100 mg/m2 (n = 5) 0.2–2.4 0.2–9.5 3.5–5.6 5.0–11.1
200 mg/m2 (n = 2) 0.3–0.7 27.8–29.6 3.2–3.3 16.6–19.3
300 mg/m2 (n = 2) 0.5–0.7 5–28.6 1.7–3.0 5.6–16.8
400 mg/m2 (n = 3) 1.1–5.7 1.7–71.3 1.7–3.4 4.6–26.6
500 mg/m2 (n = 5) 0.5–2.1 1–47.0 1–3.7 1.9–17.6
  1. Binding of samalizumab to CD200 on circulating CLL cells was evaluated by multi-parametric flow cytometry using a fluorescently-labeled monoclonal antibody specific for samalizumab (7B8) together with a second anti-CD200 antibody (IB2) specific for an epitope of CD200 distinct from the binding site of samalizumab